Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy |
| |
Authors: | Somnath Mukherjee Opal Reddy Sandhya Panch David Stroncek |
| |
Affiliation: | 1. Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA;2. Department of Transfusion Medicine, All India Institute of Medical Sciences, Bhubaneswar, 751019, Odisha, India;1. Department of Health Metric Sciences, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States;2. Division of Pathology & Laboratory Medicine, Children’s National Medical Center, Washington, DC, United States;3. Departments of Pathology & Pediatrics, George Washington University Medical School, Washington DC, United States;4. Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, United States;1. Center for Precision Medicine, Anhui No. 2 Provincial People’s Hospital, Hefei, Anhui 230041, China;2. Department of Clinical Laboratory Medicine, The Fifth People’s Hospital of Wuxi, Nanjing Medical University, Wuxi, Jiangsu, 214000, China;1. Department of Blood Transfusion, The First Affiliated Hospital of Shenzhen University School of Medicine, The Second People''s Hospital of Shenzhen, Shenzhen 518035, China;1. Department of General Surgery, Shenzhen University General Hospital, Shenzhen 518035, China;1. Department of Clinical Laboratory Medicine, The Fifth People’s Hospital of Wuxi, Nanjing Medical University, Wuxi, Jiangsu 214000, China;1. Department of Clinical Laboratory Medicine, The Fifth People’s Hospital of Wuxi, Nanjing Medical University, Wuxi, Jiangsu 214000, China;1. Department of Infectious Diseases and Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China;2. Department of Blood Transfusion, Xiangya Hospital, Central South University, Changsha, China;3. Laboratory of Ethnopharmacology Institute of Integrative Medicine, Xiangya Hospital, Central South University, Changsha, China;4. Department of PET Centre, Xiangya Hospital, Central South University, Changsha, China;1. Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, United States;2. Stanford Blood Center, Stanford Medicine, Stanford, CA 94305, United States;1. University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey;2. Y?ld?r?m Beyaz?t University, School of Medicine, Department of Internal Medicine, Division of Hematology, Ankara, Turkey;1. Apheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, ICMHO, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona Catalonia, Spain;2. Department of Hematology, ICMHO, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona Catalonia, Spain;3. Hematopathology, Department of Pathology, Centre de Diagnòstic Biomèdic (CDB), IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona Catalonia, Spain;4. Barcelona Endothelium Team, Barcelona, Spain |
| |
Abstract: | Cell processing laboratories are an important part of cancer treatment centers. Cell processing laboratories began by supporting hematopoietic stem cell (HSC) transplantation programs. These laboratories adapted closed bag systems, centrifuges, sterile connecting devices and other equipment used in transfusion services/blood banks to remove red blood cells and plasma from marrow and peripheral blood stem cells products. The success of cellular cancer immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells has increased the importance of cell processing laboratories. Since many of the diseases successfully treated by CAR T-cell therapy are also treated by HSC transplantation and since HSC transplantation teams are well suited to manage patients treated with CAR T-cells, many cell processing laboratories have begun to produce CAR T-cells. The methods that have been used to process HSCs have been modified for T-cell enrichment, culture, stimulation, transduction and expansion for CAR T-cell production. While processing laboratories are well suited to manufacture CAR T-cells and other cellular therapies, producing these therapies is challenging. The manufacture of cellular therapies requires specialized facilities which are costly to build and maintain. The supplies and reagents, especially vectors, can also be expensive. Finally, highly skilled staff are required. The use of automated equipment for cell production may reduce labor requirements and the cost of facilities. The steps used to produce CAR T-cells are reviewed, as well as various strategies for establishing a laboratory to manufacture these cells. |
| |
Keywords: | Chimeric antigen receptor T-cells Cellular therapy Cell processing Cancer immunotherapy Hematopoietic stem cell transplantation |
本文献已被 ScienceDirect 等数据库收录! |
|